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This was observed as early as 12 h after rotenone exposure, 
when pro-apoptotic mir-16 and rotenone-sensitive mir-
210 were not yet significantly perturbed. Finally, washout 
experiments demonstrated that withdrawal of rotenone led 
to counter-regulation of mir-7 and ASS1, CTH, and SHTM2 
genes. This suggests a possible role of these genes in direct 
cellular response to the toxicant, and the model appears to 
be suitable to address the processes of resilience and recov-
ery in neurotoxicology and Parkinson’s disease in future 
studies.
Keywords 3D culture · Neurotoxicity · Resilience · 
microRNA · Rotenone
Introduction
Progress in the study of toxicant-induced dopaminergic 
neurodegeneration suffers from the shortcomings of avail-
able in vivo and in vitro models, since they usually do not 
progress in the same way human disease does. Moreover, 
important aspects such as endogenous counter-regulations 
and recovery are particularly difficult to address in vitro.
Although dopaminergic neurons correspond to <1 % of 
all neurons in the brain, they play a crucial role in move-
ment, sensation of pleasure, motivation, reward, and drug 
addiction; are particularly sensitive to oxidative stress; 
and are involved in the second most common neurodegen-
erative disease—Parkinson’s disease (reviewed in Chinta 
and Andersen 2005). This neuronal cell type, therefore, 
is of particular interest for understanding the molecular 
mechanisms of PD—which are key to the development 
of preventive and disease-modifying therapies. Although 
genetic forms of PD associated with mutations in genes 
for alpha-synuclein, PARKIN, PINK1, LRRK2 or DJ-1 are 
Abstract Several shortcomings of current Parkinson’s 
disease (PD) models limit progress in identification of 
environmental contributions to disease pathogenesis. The 
conditionally immortalized cell line LUHMES prom-
ises to make human dopaminergic neuronal cultures more 
easily available, but these cells are difficult to culture for 
extended periods of time. We overcame this problem by 
culturing them in 3D with minor medium modifications. 
The 3D neuronal aggregates allowed penetration by small 
molecules and sufficient oxygen and nutrient supply for 
survival of the innermost cells. Using confocal microscopy, 
gene expression, and flow cytometry, we characterized the 
3D model and observed a highly reproducible differentia-
tion process. Visualization and quantification of neurites in 
aggregates was achieved by adding 2 % red fluorescent 
protein-transfected LUHMES cells. The mitochondrial 
toxicants and established experimental PD agents, rote-
none and MPP+, perturbed genes involved in one-carbon 
metabolism and transsulfuration pathways (ASS1, CTH, 
and SHTM2) as in 2D cultures. We showed, for the first 
time in LUHMES, down-regulation of mir-7, a miRNA 
known to target alpha-synuclein and to be involved in PD. 
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well established (reviewed in Henchcliffe and Beal 2008), 
increasing evidence suggests a role for gene–environmen-
tal interactions contributing to the sporadic form of the 
disease, and gene regulatory networks are being unraveled 
(Kumar Singh et al. 2014; Krug et al. 2014; Fujita et al. 
2014; Todorovic et al. 2014; Maertens et al. 2015; Lee 
and Cannon 2015; Rahnenführer and Leist 2015). Expo-
sure to pesticides such as rotenone may be associated with 
increased risk of PD (Ascherio et al. 2006; Costello et al. 
2009; Wang et al. 2011; Tanner et al. 2011). Mitochondrial 
dysfunctions (e.g., toxicant-induced mitochondrial com-
plex I inhibition) are believed to be central in the patho-
physiology of PD (reviewed in Franco-Iborra et al. 2015); 
however, it is not clear whether this is a primary or second-
ary event in PD pathogenesis. In addition, it is not clear yet 
why dopaminergic neurons are more vulnerable to mito-
chondrial complex I inhibition and degeneration. Thus, 
cellular responses to environmental stress and molecular 
perturbations upon toxicant insult leading to neurodegen-
eration need to be elucidated further.
There are a multitude of neuronal models for studying 
Parkinson’s disease and neurotoxicology. These include (a) 
cell lines, such as rat PC12 cell line (Greene and Tischler 
1976; Grau and Greene 2012), SH-SY5Y neuroblastoma 
cell line (Constantinescu et al. 2007; Borland et al. 2008), 
and LUHMES cell line (Lotharius et al. 2005; Zhang et al. 
2014; Ste˛pkowski et al. 2015); (b) primary cell cultures 
(Lingor et al. 1999); and (c) embryonic stem cell (ESC)- 
or induced pluripotent stem cell (iPSC)-derived neurons 
(Srikanth and Young-Pearse 2014). Different types of neu-
ronal models have strengths and limitations (Schlachet-
zki et al. 2012). The PC12 cell line, for instance, is easy 
to handle and relatively homogeneous, but is not of human 
origin—making it difficult to extrapolate interspecies dif-
ferences in response to toxicant treatment. SH-SY5Y is a 
human cell line, fast dividing but difficult to differentiate 
into postmitotic neurons (Constantinescu et al. 2007) and 
has limitations as a cancer cell line because of its relatively 
unstable genome. Primary rat midbrain cell cultures were 
established to study PD (Lingor et al. 1999), but, again, 
with an obstacle of interspecies differences. Primary post-
mortem tissues, isolated from brains of patients with PD, 
more closely reflect the pathogenesis of the disease, but are 
difficult to obtain, are already affected by the disease, and, 
therefore, unsuitable for studying the dynamics of patho-
genesis. Another limitation of primary cell cultures isolated 
from mesencephalon is low yield of biological material. In 
contrast to these primary or cancer tissue-originated cell 
models, the Lund human mesencephalic (LUHMES) cell 
line originates from healthy human 8-week-old embry-
onic mesencephalic tissue, immortalized by tetracycline-
regulated v-myc-vector transfection, and can be rapidly 
and homogeneously differentiated to mature dopaminergic 
neurons by cultivation in the presence of tetracycline, 
cAMP, and GDNF (Lotharius et al. 2005; Scholz et al. 
2011). Healthy donor origin of LUHMES makes these cells 
an attractive tool for studying the effects of environmental 
exposures leading to mitochondrial dysfunctions and/or to 
a PD-like phenotype. Human ESC and iPSC applications 
to study neurotoxicity and neurodegeneration are emerging 
and are very promising (Wheeler et al. 2015; Srikanth and 
Young-Pearse 2014), but the differentiation protocols are 
demanding, cost-prohibitive, and lengthy (up to 4/8 weeks 
of differentiation), resulting in heterogeneous neuronal 
populations. Protocols for enrichment in one cell type dur-
ing differentiation, however, are evolving (Hu et al. 2015). 
Choosing one neural model over another depends on the 
hypotheses, specific aims, and study design. Although we 
believe iPSC-derived neural models will provide a broader 
range of options in future neurotoxicological studies, we 
also need models allowing easy access to homogenous 
cell populations for mechanistic studies. In this study, we 
favored the fast-differentiating and homogenous LUHMES 
cell line for the study of early cellular perturbations and 
cellular adaptation after toxicant exposure as a promising 
PD model.
More than 50 % of known miRNAs are expressed in the 
brain (Li and Jin 2010) where they posttranscriptionally 
regulate gene expression and play important roles in cellu-
lar homeostasis, metabolism, proliferation, differentiation, 
and apoptosis. Elimination of all miRNAs results in loss 
of the dopaminergic neurons in conditional knockout ani-
mal models and stem cells (Giraldez et al. 2005; Kim et al. 
2007; Huang et al. 2010). Several miRNAs were shown 
to regulate function of dopaminergic neurons mir-133b 
(Kim et al. 2007), mir-9 (Leucht et al. 2008), and mir-132 
(Yang et al. 2012). These and other dopaminergic neuron-
specific miRNA were deficient in PD-affected midbrains 
(Kim et al. 2002; Lau and de Strooper 2010; Mouradian 
2012). mir-7, which is expressed in nigral neurons in mice 
and humans, was shown to target α-synuclein and is down-
regulated in MPP+ PD animal models (Junn et al. 2009). 
The neuroprotective role of mir-7 against MPP+-induced 
neuronal death has been suggested (Fragkouli and Doxakis 
2014; Choi et al. 2014). Thus, miRNAs may play an impor-
tant role in cellular responses to toxicant exposure and PD 
development. An increasing number of studies are address-
ing whether miRNAs are involved in cellular responses to 
environmental stress (reviewed in Smirnova et al. 2012), 
and the role of miRNAs in neurotoxicity is being elucidated 
(Huang and Li 2009; Miranda et al. 2010; Saba et al. 2012; 
Tal and Tanguay 2012; Pallocca et al. 2013; Smirnova et al. 
2014). Moreover, miRNAs play a significant role in mito-
chondrial function (Li et al. 2012), including pro-apoptotic 
mir-15, mir-16, and anti-apoptotic mir-21, mir-17-92 clus-
ter. ROS-responsive and hypoxia-related mir-210 inhibits 
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cell proliferation and represses the mitochondrial metabo-
lism and respiration by targeting several elements of the 
TCA cycle (Chan et al. 2012). mir-210, together with mir-
195, was shown to be regulated by rotenone exposure (Kim 
et al. 2013). Most importantly, there are mitochondria-
enriched miRNAs, mito-miRs (Bandiera et al. 2013), which 
may be crucial in managing the mitochondrial response to 
toxicant-induced stress.
This work is based on our collaborative studies on the 
early responses of LUHMES cells to 1-methyl-4-phe-
nylpyridinium (MPP+), the metabolite of 1-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine (MPTP), a common agent 
to experimentally induce PD (Krug et al. 2014), where 
perturbations and counter-regulations in the cells before 
mitochondrial dysfunction-initiated apoptosis were char-
acterized. Based on data obtained from metabolomics and 
transcriptomics analysis, we proposed a network of toxi-
cant (mitochondrial complex I inhibitor)-induced adap-
tations in human dopaminergic neurons before a tipping 
point is reached that allows execution of the apoptosis pro-
gram. The next question is, are these early changes perma-
nent, or can they be reversed after compound withdrawal? 
To experimentally test this, we need test systems that can 
be maintained for longer periods of time and interrogated 
for cellular perturbations, their counter-regulations, and 
ability to return to physiological conditions. LUHMES 
cells, which proved so promising in our earlier studies, 
do not allow such analysis in standard monolayer culture 
because differentiated cells tend to detach from the culture 
dish after about 9–12 days (depending on density, medium, 
and surface structuring).
3D cell cultures aiming to approximate organotypic cul-
tures are rapidly emerging (Alépée et al. 2014; Hartung 
2014), and they promise tissue-like cell density and cell/cell 
contacts. Therefore, for the first time, we have adapted the 
LUHMES cell culture to 3D using constant gyratory shak-
ing. In the first step of the current study, we adapted the 2D 
protocol to generate a 3D dopaminergic neuronal model and 
found this prolonged survival of the differentiated cells. After 
the 3D protocol optimization and characterization steps, we 
demonstrated the suitability of the 3D model for neurotox-
icity testing by using two model compounds, rotenone and 
MPP+. Finally, we analyzed the expression of miRNAs 
known to be involved in PD pathophysiology and mitochon-
drial function. We found that mir-7 was sensitive to rotenone 
treatment and that its expression recovered after rotenone 
withdrawal, while MPP+ and rotenone-responsive genes 
TYMS and MLF1IP, identified previously in Krug et al. 
(2014), were further down-regulated with time. We demon-
strated that the 3D LUHMES model is suitable for studying 
cellular responses after toxicant withdrawal and ultimately 
cellular resilience—which has previously not been possible 
in 2D because of short survival of these cultures.
Materials and methods
LUHMES maintenance and differentiation
Proliferation medium was prepared with Advanced 
DMEM/F12 (Gibco, Life Technologies) supplemented 
with 2 mM l-Glutamine (Sigma-Aldrich), 1× N2 (Gibco) 
and 0.04 μg/ml recombinant basic fibroblast growth factor 
(bFGF, R&D Systems). Differentiation medium was pre-
pared with Advanced DMEM/F12 containing 2 mM l-Glu-
tamine, 1× N2 supplement, 1 mM dibutyryl cAMP (Santa 
Cruz), 2 μg/ml tetracycline (Sigma-Aldrich), and 2 ng/ml 
recombinant human glial cell line-derived neurotrophic fac-
tor (GDNF, Gemini). For propagation and differentiation 
in monolayer, all flasks and plates were pre-coated with 
50 μg/ml poly-l-ornithine (PLO) and 1 μg/ml fibronectin 
for 12 h prior to the experiment.
Wild-type LUHMES (ATCC® CRL_2927™) human 
neuronal precursor cells, as well as genetically modified 
LUHMES, ubiquitously expressing red or green fluorescent 
protein (RFP/GFP) were cultured as described previously 
(Scholz et al. 2011). RFP- and GFP-expressing cell lines 
were generated earlier as described in Schildknecht et al. 
(2013). Briefly, the conditionally immortalized cells (v-myc 
transgene expressing, controlled by a tet-off system) were 
maintained in proliferation medium in PLO–fibronectin 
pre-coated Nunclon™ (Nunc) flasks and passaged every 
2–3 days. For differentiation in 2D (Fig. 1a, 2D diff pro-
tocol), cells were seeded in a pre-coated 175-cm2 flask 
(Nunc) in proliferation medium. After 24 h, medium was 
changed to differentiation medium. After 48 h in differenti-
ation medium, cells were trypsinized using TripleE Express 
(Life Technologies) and seeded at a density of 5 × 105 cells 
per 2 ml per well in pre-coated 6-well plates (Nunc™ Cell 
culture-treated). Medium was exchanged every second day.
To induce neuronal differentiation in 3D, LUHMES 
progenitors were trypsinized using TryplE Express, cen-
trifuged, and resuspended in differentiation medium. Cells 
were seeded in 6-well plates (Falcon®) at 5 × 105 cells/well 
in 2 ml of differentiation medium and placed on a gyra-
tory shaker (ES-X, Kuhner shaker) at 80 rpm in a humidi-
fied incubator (37 °C, 10 % CO2). Medium was exchanged 
every third day by removing 1.2 ml and adding 1.5 ml of 
fresh medium (Fig. 1a, 3D diff protocol). Following proto-
col 3D + T10 (Fig. 1a) on day 3 of differentiation, aggre-
gates were treated with 10 nM taxol (>97 % paclitaxel, 
T7191 Sigma-Aldrich), an anti-proliferation compound, 
for 48 h. On day 5, aggregates were washed directly in 
the well with washing medium (supplemented with l-glu-
tamine, N2, and tetracycline), and differentiation medium 
was added to continue cellular differentiation. For co-cul-
tures of wild-type LUHMES with RFP- or GFP-expressing 
cells, 1 × 104 RFP or GFP cells were seeded with 5 × 105 
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Fig. 1  Adaptation and optimization of 3D LUHMES differentiation pro-
tocol. a The original 2D differentiation (2D diff protocol) was adapted 
for 3D culture (3D diff protocol) by subjecting the single-cell suspension 
to continuous gyratory shaking. Protocol 3D pre-diff involves a pre-dif-
ferentiation step in 2D for 2 days, trypsinization, and subsequent culti-
vation in 3D. Further optimization involved adding the anti-proliferation 
compound taxol on day 3 for 48 h (10 nM, 48 h) to reduce cell prolifera-
tion (3D + T10 protocol). Toxic compound treatment took place between 
days 6 and 8 for 12, 24, and 48 h, reversely. Samples for toxicological 
end points were collected immediately after treatment on day 8 or on day 
15 after washout of compounds and 7 days recovery. b Differentiation 
of LUHMES in monolayer. As differentiation advances, cells may detach 
from the surface (d9, last photograph). c Aggregate formation under con-
tinuous gyratory shaking (80 rpm). Note the increasing size of aggre-
gates in course of differentiation. d Treatment of 3D cultures with anti-
proliferation drug taxol (10 nM) for 48 h blocked the proliferation and 
slowed down aggregate growth. e Measurements of aggregate size dur-
ing differentiation following different 3D protocols. At least 100 aggre-
gates were measured per condition, per day, in at least three independ-
ent experiments, with exception of 3D pre-diff. and 3D gradient speed, 
where only one independent experiment was conducted. Data represent 
mean ± SEM, n ≥ 3 (independent experiments). Scale bars are 200 μm
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LUHMES-WT cells to comprise 2 % of the total cell popu-
lation. Upon seeding, cells were differentiated as described 
above on a gyratory shaker at 80 rpm in a humidified incu-
bator (37 °C, 10 % CO2).
Chemical preparation, storage, and treatment
A 2 mM taxol stock was prepared in 100 % DMSO (D2650, 
Sigma-Aldrich), aliquoted, and stored at −20 °C. A 10 mM 
MPP+ iodite (>98 % HPLC powder, D048 Sigma-Aldrich) 
stock was prepared in sterile H2O, aliquoted, and stored at 
−20 °C protected from light. A 100 mM rotenone (>95 % 
powder, 84–79–4 Sigma-Aldrich) stock was prepared in 
100 % DMSO, aliquoted, and stored at −20 °C protected 
from light. Once defrosted, aliquots were used immediately 
and discarded after use.
On day 3 of differentiation, aggregates were treated 
with taxol (10 nM, for 48 h) to reduce the number of pro-
liferating cells. Test compounds (MPP+ and rotenone) 
were added to cultures on days 6, 7, or 7.5 for 48, 24, and 
12 h, respectively. DMSO was used as a solvent control. 
End concentration of DMSO used in the cultures was 
≤0.001 %, which did not have any effects on cell viability. 
Samples for toxicological end points were collected on day 
8. To study cellular recovery, the toxicants were washed out 
on day 8. Cells were washed once with medium directly in 
the plate (supplemented with l-Glutamine, N2, and tetra-
cycline) and plated in a new 6-well plate with fresh differ-
entiation medium. Medium was exchanged on days 10 and 
12. On day 15, aggregates were collected to measure end 
points relevant to cellular recovery from the effects of rote-
none or MPP+ exposure.
Cell viability
Cell viability (mitochondria activity) was analyzed using 
the resazurin reduction assay. A 1 mg/ml resazurin sodium 
salt (Sigma-Aldrich) stock was prepared in PBS. 200 μl 
of 1 mg/ml stock was added to each well (2 ml medium), 
and plates were kept on a gyratory shaker at 80 rpm in a 
humidified incubator (37 °C, 10 % CO2) for 1.5 h. 100 μl 
of samples was transferred from each well in triplicates 
into 96-well plates, and fluorescence was measured in a 
fluorescence plate reader (530 nm excitation/590 nm emis-
sion). Differentiation medium was incubated with resazurin 
in parallel as a blank control. Cell viability (mitochondria 
activity) was calculated as % of fluorescence intensity rela-
tive to solvent-treated controls after subtracting blanks in 
three biological replicates.
Cytotoxicity (membrane integrity) was analyzed using 
the LDH release assay (Promega). As a positive con-
trol, aggregates were treated with 1 % Triton X100. 50 μl 
of medium from each well was transferred to a 96-well 
plate. 50 μl of LDH substrate was added to each well. 
The plate was incubated for 30 min at room temperature 
in the dark. Differentiation medium was incubated with 
substrate in parallel as a blank control. The reaction was 
stopped with 50 μl stop solution. Absorbance was recorded 
at 490 nm. After subtracting blanks, cytotoxicity (%) was 
determined by normalization of ODs from the test sample 
to positive and solvent-treated controls.
Mitochondrial activity
Mitochondrial activity after rotenone treatment was meas-
ured using the red fluorescent dye Mitotracker® Red 
CMXRos (Life Technologies) following the manufac-
turer’s instructions. Briefly, after 48-h rotenone exposure, 
aggregates were transferred into 24-well plates and incu-
bated with 1 μM Mitotracker® Red on a gyratory shaker 
at 80 rpm at 37 °C, 10 % CO2 for 30 min. Aggregates were 
washed twice with PBS and fixed with 4 % PFA for 20 min 
at 4 °C. Fixed aggregates were washed twice in PBS and 
mounted on slides for fluorescence imaging (excitation 
579 nm/emission 599 nm). In every independent experi-
ment, at least 10 single aggregates were imaged per condi-
tion, and the mean gray value (sum of the gray values of 
all the pixels in the area divided by the number of pixels 
in the area) per aggregate was quantified using the open-
source ImageJ software (http://imagej.nih.gov/ij/) and nor-
malized to solvent-treated controls. Average of normalized 
mean gray values ± SEM was calculated from at least three 
biological replicates. Differences in treated and control 
samples were analyzed for statistical significance using 
Kruskal–Wallis test followed by Dunn’s Multiple compari-
son test. p value  is denoted on graphs by ***.
Size measurements
Aggregates were cultured as described above, and phase-
contrast microscopic images were taken on days 3, 6, 9, 12, 
15, and 21 of differentiation. The diameter of 20–50 aggre-
gates was measured on each day using SPOT software 5.0 
(Diagnostic Instruments, Inc.). Experiments were repeated 
at least three times.
Flow cytometry
2D and 3D differentiated, as well as undifferentiated, 
LUHMES cells were trypsinized directly in the plate 
on the shaker with TryplE Express containing 4 units/
ml DNAse at 37 °C for 30 min. After 30 min, aggregates 
were homogenized by aspiration using a 1-ml syringe 
with 26G3/8 needle. Single-cell suspensions in 2D were 
obtained by pipetting up and down several times. The 
previously described protocol (Smirnova et al. 2015a) 
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was followed for further steps. Briefly, cells were fixed 
with 2 % PFA and stained with Alexa Flour 647 mouse 
antihuman Ki-67 antibody (1:20, clone B56, BD 
Pharmingen™) at 4 °C for 1 h in PBS/1 %BSA/0.15 % 
saponin/10 % goat serum. Ki-67 expression was quan-
tified using a FACSCalibur flow cytometer (BD). 
Unstained cells, as well as cells stained with Alexa Flour 
647 mouse IgG1 κ Isotype control, were used to set the 
gates for Ki-67-negative cells.
Immunocytochemistry and confocal imaging
For immunostaining, aggregates were collected on 
days 6, 12, 15, or 21 of differentiation, and immuno-
cytochemistry was performed as previously described 
(Smirnova et al. 2015a) with some adaptations for 3D 
cultures. Briefly, aggregates were fixed with 4 % PFA 
(20 min, 4 °C) and blocked with blocking solution 
[10 % goat serum (Sigma), 1 % BSA (Sigma), 0.15 % 
saponin in PBS] for at least 1 h on a shaker at 4 °C. 
Subsequently, aggregates were incubated with primary 
antibodies diluted in blocking solution for 48 h at 4 °C on 
a shaker. The following antibodies were used; they are as 
follows: rabbit antihuman neurofilament (NF200, 1:200, 
Sigma); mouse antihuman MAP2 (1:100, Sigma); mouse 
antihuman NeuN (1:100, Millipore); mouse antihuman 
synaptophysin (1:200, Millipore); rabbit antihuman Ki-67 
(1:100, Santa Cruz). As negative control, aggregates 
were incubated with blocking solution. Then, aggregates 
were washed twice and incubated for 24 h at 4 °C on 
a shaker in the dark with secondary antibodies (goat 
antimouse IgG Alexa Fluor® 488 and goat antirabbit IgG 
Alexa Fluor® 568, 1:500, Life Technologies). After 24 h, 
aggregates were washed, and nuclei were stained with 
Hoechst 33342 (1 μg/ml, Invitrogen, Molecular Probes) 
for at least 1 h at RT. Aggregates were then mounted 
using mounting medium (Immu-Mount™, Thermo Sci-
entific) on glass slides (Fisherbrand® Thermo Scientific) 
and analyzed using the Zeiss LSM 510 Confocal III con-
focal microscope (Zeiss) and ZEN Imaging software 
(Zeiss).
For dye penetration assays, LUHMES ubiquitously 
expressing GFP were used. GFP-LUHMES were differenti-
ated in 3D for 12 days following 3D diff protocol (Fig. 1a). 
On day 12 of differentiation, Hoechst 33342 (1 μg/ml) was 
added to the cultures for 5, 15, 30, 60 min, or 6 h. Aggre-
gates were then fixed with 4 % PFA, incubated with opti-
cal clearing solution (ScaleA2: 4 M urea, 10 % wt/vol 
glycerol, 0.1 % wt/vol Triton-X-100, pH 7.7 (Hama et al. 
2011) for further 48 h at 4 °C on a shaker and mounted on 
the glass slides. Hoechst 33342 penetration through the 
aggregates was analyzed using Zeiss LSM 510 confocal III 
microscope.
Neurite integrity quantification
To assay neurite integrity, RFP-expressing LUHMES were 
mixed with wild-type LUHMES in a ratio 1:49. Cells were 
differentiated following 3D + T10 protocol. On day 6, cells 
were exposed to 0.1 μM rotenone or DMSO as control. After 
48-h exposure, aggregates were collected, fixed with 4 % 
PFA, and nuclei were stained with 1 μg/ml Hoechst 33342. 
Then, aggregates were incubated with ScaleA2 solution for 
further 48 h at 4 °C on a shaker and mounted on glass slides 
for imaging by confocal microscopy. The hyperstack images 
were analyzed using the software KNIME with the Image 
Processing plugin. The program provides algorithms and 
means for image (pre) processing, filtering, segmentation, 
and feature calculation. The provided algorithms are well 
known and common image analysis techniques that can be 
combined to fit arbitrary analysis problems. In order to quan-
tify the neurites, edge detection was applied to the images to 
highlight the neurites. Then, the neurite areas as well as the 
cell bodies were segmented. After cell bodies were excluded 
from the analysis, the area of the identified neurites for every 
slice of the hyperstack was calculated and normalized to 
the number of red cells in the aggregate. Lastly, the median 
neurite area within the hyperstack was calculated in three 
biological replicates (mean ± SEM). Differences in rote-
none-treated and DMSO-treated samples were analyzed for 
statistical significance using the Mann–Whitney test; p value 
<0.01 is denoted on the graphs by **.
Apoptosis assays
Two assays were used to estimate the level of apoptosis 
during 3D differentiation (3D diff protocol). The number 
of apoptotic/necrotic cells was quantified using PE Annexin 
V Apoptosis Detection kit I (BD Pharmingen™) by flow 
cytometry and visualized using the Cell Event® Cas-
pase-3/7 Green Detection Reagent (Life technologies) by 
confocal fluorescent microscopy. For Annexin V-PE/7AAD 
staining, aggregates were trypsinized for 30 min with Try-
plE Express, washed once with PBS, and resuspended in 
1× Annexin V binding buffer. 4 × 105 cells were stained in 
100 μl with 5 μl Annexin V-PE and 5 μl 7-AAD for 15 min 
at room temperature protected from light. Unstained cells 
and cells stained either with Annexin V or 7-AAD were 
used to set the gates. Cells treated with 0.5 μM rotenone 
were used as positive control. The percentage of Annexin 
V-positive cells, 7-AAD-positive cells, and double-positive 
cells were quantified using a FACSCalibur flow cytom-
eter (BD). For caspase 3/7 staining, upon addition of the 
Cell Event reagent and 1 μg/ml Hoechst 33342, cells were 
incubated at 37 °C for 60 min, washed once with PBS, and 
fixed with 4 % PFA for 20 min at 4 °C on a shaker. Fixed 
aggregates were washed twice with PBS and mounted on 
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slides for fluorescence imaging using Zeiss LSM 510 con-
focal III microscope. Undifferentiated LUHMES were used 
as negative control in both experiments.
RNA extraction, Reverse Transcription, and Real‑Time 
PCR
Total RNA was extracted using either TRIzol® Reagent 
(Life Technologies) or the miRVANA miRNA isolation kit 
(Ambion, Life Technologies) following the manufacturer’s 
instructions. RNA integrity was measured using the Nan-
odrop 2000 (TermoScientific) UV–Vis Spectrophotometer 
(260 nm).
Equal amounts of purified RNA (500 ng) were reverse 
transcribed to cDNA using random hexamer primers (Pro-
mega) and M-MLV reverse transcriptase Kit (Promega) fol-
lowing the manufacturer’s instructions. A DNAse treatment 
step was included in cDNA synthesis to ensure the elimina-
tion of DNA traces. cDNA was diluted 1:5, and qRT-PCR 
was performed. Expression of neuronal markers during 
LUHMES differentiation was analyzed using TaqMan gene 
expression assay (Life Technologies) and TaqMan advance 
Master Mix (Life Technologies) according to the manufac-
turer’s protocols. Expression of genes perturbed by toxicant 
treatment was analyzed using Fast SYBR Green master 
mix (Life Technologies) and primers listed in Supplemen-
tary Table S1. 18S and GAPDH were used as housekeeping 
genes for TaqMan gene expression and SYBR Green PCRs, 
respectively. All RT-PCRs were performed in duplicates on 
Fast Applied Biosystems 7500 System (Life Technologies) 
with the following thermal cycling parameters: SYBR® 
Green RT-PCR (95 °C for 20 s, followed by 40 cycles of 
3 s at 95 °C and 30 s 60 °C); a melting curve step was 
included in SYBR Green reactions (95 °C for 15 s, 60 °C 
for 1 min, 95 °C for 15 s, and 60 °C for 15 s); TaqMan gene 
expression assay (95 °C for 20 s, followed by 40 cycles of 
3 s at 95 °C and 30 s 60 °C).
For miRNA amplification, short stem-loop cDNA 
libraries from individual miRNAs were generated using 
TaqMan® microRNA assays and TaqMan® microRNA 
reverse transcription kits (Life Technologies). Up to six 
miRNAs were multiplexed in one reaction. Quantita-
tive real-time PCR on miRNAs was performed using 
the TaqMan® microRNA assay kit in combination with 
TaqMan® FAST advanced PCR master mix, (Life Tech-
nologies) with the following thermal cycling parameters: 
95 °C for 20 s, followed by 40 cycles of 3 s at 95 °C and 
30 s 60 °C. Expression of individual miRNAs was nor-
malized to RNU44 expression and was shown relative to 
expression in solvent-treated LUHMES.
The relative mRNA and miRNA expression was quantified 
using the comparative CT (2−∆∆CT) method (Schmittgen and 
Livak 2008). Data collected from three to four independent 
experiments were calculated as average log2-fold change 
in independent biological replicates ± SEM. Differences 
in treated and control samples were analyzed for statistical 
significance using one-way ANOVA test followed by Dun-
nett’s post hoc test. p value <0.05 is denoted on graphs by *, 
p < 0.01 by **, and p < 0.001 by ***, respectively.
Results
Protocol adaptation and optimization for LUHMES 
differentiation in 3D
Differentiation of LUHMES cells in monolayer culture 
(Fig. 1a, b, 2D diff protocol) was well established and 
extensively characterized earlier (Scholz et al. 2011; Schil-
dknecht et al. 2013), and the described changes in mor-
phology, proliferation (Ki-67), and differentiation (Map2 
and NF200) have been reproduced here (Supplementary 
Figure S1a). However, LUHMES cells differentiated in 
monolayer have limited life span. With increasing culture 
age, the interaction of the large neurite network with the 
extracellular matrix (plate coating) weakens, and the net-
work either contracts into ganglion-like structures or fully 
detaches from the plate (Fig. 1b, last panel, d9). The brief 
survival of the differentiated cultures in 2D (which allows 
acute toxicity studies) is an obstacle for long-term, low-
dose toxicological studies, as well as for cellular adaptation 
and resilience studies after toxicological stress. Therefore, 
we modified and adapted the LUHMES differentiation 
protocol for 3D. The 3D LUHMES model was prepared 
using the gyratory shaking technique as established for 
3D rat primary aggregating brain cell cultures (Honegger 
and Monnet-Tschudi 2001; van Vliet et al. 2008) and iPSC 
microphysiological systems (Hogberg et al. 2013) with few 
modifications (Fig. 1a, c, 3D diff protocol).
First, the size of aggregates was monitored during differ-
entiation. By adjusting initial cell number and shaker speed, 
we were able to control aggregate size (Fig. 1e, 3D diff). 
The cultivation of the aggregates from day 0 of differentia-
tion under a constant shaking speed of 80 rpm allowed us to 
keep the size of aggregates within 300–425 μm in diameter 
through 21 days of differentiation, while under a gradually 
increasing speed from 68 to 80 rpm during the first 5 days, 
as originally established for rat primary cultures (Honegger 
and Monnet-Tschudi 2001), LUHMES aggregates reached 
700 μm in diameter (Fig. 1e, 3D gradient).
Second, in order to test sufficient oxygen and nutrient 
supply, early apoptosis (Annexin V and caspase 3/7-posi-
tive cells) and necrosis (7-AAD-positive cells) were moni-
tored by flow cytometry and fluorescence microscopy. 
Although a low percentage of caspase 3/7-positive cells 
were detectable on day 21 of differentiation (Fig. 2a), 
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caspase 3/7-positive cells were distributed equally through-
out the aggregates without any visible accumulation in the 
middle of the aggregates. No increase in Annexin V-posi-
tive cells was observed during the 21 days of differentiation 
in 3D (Fig. 2b). The percentage of Annexin V- and 7AAD-
positive cells in the 3D cultures was comparable to those in 
monolayer undifferentiated LUHMES cultures, which were 
subjected to the same preparation procedure—both cultures 
were trypsinized for 30 min prior to Annexin V/7-AAD 
staining.
Third, we investigated compound penetration by stain-
ing the live, 12-day-old aggregates with DNA-binding 
blue fluorescent dye, Hoechst 33342 trihydrochloride, 
MW = 616 g/mol (Invitrogen) for 5, 15, 30, 60 min, and 
6 h. For this experiment, LUHMES ubiquitously expressing 
GFP were used (Schildknecht et al. 2013). Hoechst 33342 
dye penetration throughout the aggregates was advancing 
with increasing incubation time. Hoechst 33342 reached 
the middle of the aggregates after 1 h of treatment (Fig. 2c, 
Supplementary Figure S1b). This experiment ensured suf-
ficient penetration of necessary small molecule factors for 
differentiation and nutrients, as well as toxicants. In addi-
tion, no visible apoptotic nuclear fragmentation accumu-
lated in the middle of aggregates (Fig. 2c, 1 and 6 h). Thus, 
3D cultures could be kept at least twice as long in culture 
than their 2D counterparts.
Finally, withdrawal of FGF and the addition of tetracy-
cline, cAMP, and GDNF should rapidly induce exit from 
the cell cycle and differentiation to postmitotic mature neu-
rons. We suggest that the observed continuous increase in 
the size of aggregates during differentiation could be due 
to a prolonged proliferation in 3D differentiating cultures. 
Higher cell density and increased cell-to-cell interac-
tions may stimulate signaling between the cells within the 
aggregates that impedes exit from the cell cycle. There-
fore, we quantified the expression of Ki-67, a proliferation 
Fig. 2  Quantification of apoptosis and necrosis level in 3D 
LUHMES model. a Caspase 3/7 activation (green nuclei) as an early 
apoptotic marker was visualized using fluorescent microscopy in 
combination with Hoechst 33342 staining of nuclei (blue) in undif-
ferentiated LUHMES monolayer cultures (d0) and 21 days after 
induction of differentiation in 3D. Scale bars are 50 μm. b Annexin 
V/7-AAD-positive cells were quantified using flow cytometry on day 
0 (as negative control) and days 12, 15, and 21 following 3D diff. 
protocol for differentiation. Aggregates exposed to 0.5 μM rotenone 
for 48 h and after 7 days recovery were used as a positive control 
(last panel). Annexin V-positive cells are in early apoptosis; double 
stained for Annexin V and 7AAD cells are in later apoptotic phases, 
while 7-AAD-positive cells represent a population of necrotic cells. 
Data are shown as mean ± SEM, n ≥ 3 (independent experiments) 
c Penetration assay with Hoechst 33342: 12-day-old aggregates of 
GFP-expressing LUHMES were differentiated according to 3D diff 
protocol and were stained for increasing time intervals with Hoechst 
33342. Confocal optical slices through the center of the aggregates 
are shown to demonstrate time-dependent penetration of Hoechst 
33342 through the aggregates. Compare GFP expression (green) at all 
time points in the center of aggregates with the absence of Hoechst 
33342 staining (blue) after 5, 15, and 30 min of incubation and pen-
etration of Hoechst 33342 to the middle after 1 and 6 h of incubation. 
No apoptotic nuclei are visible in the center of aggregates (60 min 
and 6 h). Scale bar is 100 μm (color figure online)
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marker, in undifferentiated cells as well as in 2D and 3D 
cultures. As expected, undifferentiated LUHMES were 
98 ± 2 %-positive for Ki-67. Induction of differentiation in 
2D reduced the expression of Ki-67 to 16 % by day 6, while 
in 3D cultures 49 ± 13 % of the cells were still Ki-67-pos-
itive on day 6 and 47 ± 12 % on day 12 (Fig. 3a, Supple-
mentary Figure S1c). Therefore, we optimized the 3D diff 
protocol further to accelerate the exit from cell cycle in 3D 
and induce homogeneous differentiation. In the first step, 
we evaluated whether pre-differentiation in 2D for 48 h 
before 3D differentiation (Fig. 1a, 3D pre-diff protocol) 
would decrease proliferation. No differences in the size of 
aggregates (Fig. 1e, 3D pre-diff), as well as no change in 
Ki-67 expression (data not shown), were observed, com-
pared to the 3D diff protocol; this protocol, therefore, was 
not followed further. In the second step, we tested whether 
increasing the tetracycline concentration would reduce the 
proliferation rate. LUHMES were differentiated according 
to the 3D diff protocol in the presence of 2, 4, and 10 μg/
ml tetracycline. Although the highest tetracycline concen-
tration reduced the proportion of proliferating Ki-67 cells 
(Supplementary Figure S1d), it appeared to be cytotoxic 
for the cultures (observation based on aggregate morphol-
ogy, data not shown). Next, we applied treatment with the 
mitotic inhibitor taxol (also known as paclitaxel). The sup-
plementation of neural differentiation media with anti-pro-
liferation drugs, such as cytosine arabinofuranoside (AraC), 
is common and broadly used in primary neuronal cultures 
to block the proliferation of neuroprogenitors and astroglia 
without affecting postmitotic neurons (Gerhardt et al. 2001; 
Volbracht et al. 2006) After optimization experiments, 
10 nM taxol for 48 h, from days 3 to 5 of differentiation, 
was chosen as a treatment scheme (Fig. 1a, 3D + T10 pro-
tocol). Treatment with taxol led to a reduction in aggregate 
size (250–300 μm on average, Fig. 1d, e, 3D + T10) and 
significant decreased in Ki-67-positive cells to 6 ± 6 % on 
Fig. 3  Estimation of proliferation rate within the aggregates. a Per-
centage of Ki-67-positive cells on days 6 and 12 of differentiation 
with or without taxol in comparison with undifferentiated LUHMES 
(d0). The number of Ki-67-positive cells was measured using Alexa 
Flour 647-conjugated anti-Ki-67 antibody by flow cytometry. Data 
represent mean ± SD, n ≥ 3 (independent experiments). b Ki-67 
gene expression on days 0, 6, and 12 of differentiation in 3D diff 
and 3D + T10 cultures. Data are normalized to Ki-67 expression on 
d0 and represent mean ± SEM, n ≥ 3 (independent experiments). c 
Immunostainings of 3D diff and 3D + T10 aggregates with antibody 
against KI-67 showing prolonged presence of Ki67-positive cells 
(red) in 3D diff cultures in comparison with 3D + T10 aggregates. 
The aggregates were co-stained with postmitotic neuronal marker 
NeuN (green). The nuclei were visualized with Hoechst 33342 stain-
ing. Scale bars are 50 μm. The aggregates were fixed on glass slides 
and covered with coverslips for confocal imaging, which explains the 
larger size of the aggregates in comparison with Fig. 1, where floating 
aggregates were imaged (color figure online)
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day 6 and 2 ± 2 % on day 12 of differentiation (Fig. 3a, 
Supplementary Figure S1c). In addition, we analyzed the 
expression of the Ki-67 gene prior to and six and 12 days 
after induction of differentiation following either 3D diff or 
3D + T10 protocols by real-time RT-PCR (Fig. 3b), which 
confirmed our flow cytometry data. The effects of taxol on 
Ki-67-positive cells were confirmed morphologically by 
immunocytochemistry, where whole aggregates were fixed 
at different stages of differentiation and stained with anti-
bodies against Ki-67 and the postmitotic neuronal marker, 
NeuN (Fig. 3c). Fewer Ki-67-positive cells and higher 
number of NeuN-positive cells were found in 3D + T10 
samples on days 6 and 12 of differentiation in comparison 
with 3D diff samples. Supplementation of LUHMES dif-
ferentiation medium with taxol for 48 h selectively blocked 
proliferation without any negative effects on neuronal cells, 
increased the homogeneity of the cell population, and did 
not interfere with further toxicological studies since taxol 
was washed from the cultures before toxicant exposures. 
Thus, we favored the 3D + T10 protocol over other dif-
ferentiation conditions, and this protocol was followed as 
a standard differentiation protocol for further experiments.
Characterization of LUHMES differentiation in 3D
The differentiation in 3D was characterized by immuno-
cytochemistry. In addition to Ki-67 and NeuN stainings 
(described above), aggregates were stained with further 
neuronal markers (MAP2 for dendrites and apical part of 
axons, neurofilament (NF200) for axons, and synapto-
physin for synapses) at different stages of differentiation 
with (3D + T10) and without (3D diff) taxol treatment. 
Induction of differentiation in 3D induced the expression 
of MAP2, NeuN, and synaptophysin; reduced the expres-
sion of Ki-67; and changed the morphology of neurofila-
ment- and MAP2-positive neurites (Figs. 3c, 4). Interest-
ingly, treatment with taxol not only inhibited proliferation, 
but significantly enhanced maturation, dendritic morpho-
genesis, and arborization as shown for MAP2 and synap-
tophysin stainings (Figs. 4, 5a). For more detailed visuali-
zation of long neurites protruding from the differentiated 
neurons, high magnification of MAP2/NF200 and synap-
tophysin/NF200 stainings of taxol-treated aggregates is 
shown (Fig. 5b). These findings are in agreement with pub-
lications showing that low taxol concentrations promote 
Fig. 4  Immunocytochemis-
try of neuronal differentiated 
LUHMES in 3D diff and 
3D + T10 cultures on days 6, 
12, 15, and 21 after induction of 
differentiation. Panel a shows 
the induction of expression of 
MAP2 (green) and NF200 (red), 
as well as maturation and neu-
rite elongation in 3D cultures 
followed 3D +T10 protocol 
versus 3D diff protocol over a 
span of 21 days of differentia-
tion. Panel b shows the overlay 
of NF200 (red) and typical 
punctual staining with synaptic 
marker, synaptophysin (Syn, 
green). Note higher synapto-
physin expression in 3D + T10 
cultures versus 3D diff cultures. 
The nuclei were visualized with 
Hoechst 33342 staining. Scale 
bars are 50 μm. The aggregates 
were fixed on glass slides and 
covered with coverslips for con-
focal imaging which explains 
the larger size of the aggregates 
in comparison with Fig. 1, 
where floating aggregates were 
imaged (color figure online)
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lamellipodial protrusions, stabilize microtubules, and 
increase spine formation (Buck and Zheng 2002; Gu et al. 
2008).
Real-time PCR was performed to analyze induction of 
neuronal genes during differentiation of LUHMES in 3D. 
Expression of general neuronal markers (β-III-tubulin, 
NeuN, synapsin1), marker genes specific for dopaminergic 
neurons [tyrosine hydroxylase (TH), dopamine transporter 
(DAT), and vesicular monoamine transporter member 
2 (VMAT2)], as well as proliferation and neural precur-
sor markers Ki-67 and Nestin, were analyzed in course of 
3D + T10 differentiation and normalized to the expression 
levels at day 0 (Fig. 5c). Ki-67 and Nestin were down-reg-
ulated during differentiation, while expression of neuronal 
markers was significantly induced (one-way ANOVA test 
followed by Dunnett’s post hoc test). The expression levels 
of these marker genes were similar to those in 2D differen-
tiated LUHMES (Fig. 5d) with slightly higher expression 
of TH in 3D cultures versus 2D. Note that the expression 
level of all genes plateaued on day 6 of differentiation, sug-
gesting complete differentiation.
LUHMES 3D model for neurotoxicity testing
Next, we analyzed the performance of the 3D model for 
neurotoxicity testing by applying two well-known neuro-
toxicants, MPP+ and rotenone. Both chemicals are mito-
chondrial complex I inhibitors and cause Parkinsonism 
(Betarbet et al. 2000; Franco-Iborra et al. 2015). MPP+ is 
specific for dopaminergic neurons, because of its selec-
tive uptake by them (Langston et al. 1984), while rotenone 
has broader toxicity. LUHMES neuronal aggregates were 
treated with increasing concentrations of both compounds 
for 24 and 48 h. First, cell viability assay, based on mito-
chondria metabolic capacity, was performed to gener-
ate concentration–response curves (Fig. 6a, b). Second, a 
cytotoxicity assay, based on the measurement of membrane 
integrity, was conducted in the same samples using LDH 
release assay (Supplementary Figure S2). As expected, 
mitochondria impairment was measured at concentrations 
at which the cellular membrane was still intact (low LDH 
activity in the media), confirming the mitochondria selec-
tivity of the test compounds by the higher sensitivity of the 
resazurin reduction-based assay. The concentrations (5 μM 
MPP+ and 0.1 μM rotenone) with slight mitochondria 
impairment after 24- and 48-h exposure were used for fur-
ther gene expression and washout experiments.
As a proof of concept, compound washout experiments 
were performed to address counter-regulation responses 
after short-term exposure in comparison with long-term 
chronic exposure. LUHMES were differentiated in 3D and 
exposed to 0.1 μM rotenone and 5 μM MPP+ for 12, 24, 
48, or 192 h. On day 8 of differentiation, after 12, 24, and 
Fig. 5  Enhanced neuronal maturation in 3D + T10 cultures. a MAP2 
staining of representative aggregates differentiated for 12 days follow-
ing either 3D +T10 (first panel) or 3D diff. (second panel) protocols. 
The nuclei were visualized with Hoechst 33342 staining. b Higher 
magnification (63×) of representative aggregates differentiated for 
12 days under 3D + T10 conditions and stained with synaptophysin 
(green), NF200 (red) in the first slide and MAP2 (green), NF200 (red) 
in the second slide. The nuclei were visualized with Hoechst 33342 
staining. Scale bars are 50 μm. Real-Time RT-PCR of genes involved 
in LUHMES neuronal differentiation and maturation. LUHMES were 
differentiated in 3D + T10 (c) and 2D monolayer cultures (d). RNA 
samples were collected on days 3, 6, 9, 12, 15, and 21 of differentia-
tion and prior induction of differentiation (day 0) as a control. Data 
represent mean of log2 (fold change) ± SEM normalized to d0 from 
at least four independent experiments. Statistical significance was cal-
culated using one-way ANOVA test followed by Dunnett’s post hoc 
test. Expression of all genes was significantly (p < 0.05) different in 
comparison with day 0, except Nestin in 3D cultures and Ki-67 in 2D 
cultures (Supplementary Table S2) (color figure online)
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48 h of exposure, compounds were washed out, and aggre-
gates seeded into new plates and cultivated further until day 
15. In case of 192-h exposure, aggregates were exposed to 
the toxicants continuously from day 7 until day 15. Cell 
viability (resazurin reduction assay) was assessed for all 
exposure conditions on day 15 of differentiation (Fig. 6c). 
Continuous exposure (192 h) to 5 μM MPP+ was 100 % 
toxic for LUHMES, while exposure to 0.1 μM rotenone 
for 192 h reduced cell viability by 70 %. Interestingly, 
after MPP+ wash out, around 80 % of cells were lost by 
day 15. This suggested either that MPP+ accumulates in the 
aggregates and continues to affect mitochondria after wash 
out, or that processes initiated by 5 μM MPP+ cannot be 
reversed, and cells cannot recover from the primary hit (at 
least at this concentration) (Fig. 6c dark gray line).
The washout effect was different for varying durations 
of 0.1 μM rotenone exposures (Fig. 6c light gray line). 
Exposure for 12 and 24 h further reduced viability by 34 % 
in total, while cells treated with 0.1 μM rotenone for 48 h 
were more strongly affected (47 % decrease in viabil-
ity). However, although 5 μM MPP+ was less toxic than 
rotenone immediately after the hit (day 8), its withdrawal 
could not rescue cells from ongoing cell death, while in 
samples treated with 0.1 μM rotenone, cell viability con-
tinued to decline but to lesser extent than in MPP+ samples.
Since mitochondria are the primary target for rotenone, 
we further evaluated the effects of rotenone on mito-
chondrial membrane potential in individual aggregates. 
LUHMES were differentiated following 3D + T10 proto-
col, exposed to 0.05, 0.1, and 0.5, 1 and 10 μM rotenone 
or DMSO from d6 to d8 of differentiation. After 48-h 
exposure to rotenone, the aggregates were stained with 
the MitoTracker dye, to allow its accumulation in mito-
chondria according to the magnitude of their membrane 
potential. The mean fluorescence intensity values were then 
estimated in individual aggregates by fluorescence micros-
copy and normalized to DMSO controls (Fig. 6d, n ≥ 3, 
independent experiments with 10–20 aggregates assayed 
per experiment). Mitochondrial activity was significantly 
reduced in rotenone-treated samples. High correlation 
between data from resazurin and MitoTracker assays was 
observed for lower rotenone concentrations (0.05, 0.1, and 
Fig. 6  Cell viability of LUHMES aggregates after exposure to rote-
none and MPP+. LUHMES cells were differentiated following 
3D + T10 protocol and exposed reversely to different rotenone (a) 
and MPP+ (b) concentrations from day 6 to 8 (48 h) and from day 7 
to 8 (24 h). c Cell viability after toxicant washout and recovery period. 
LUHMES were exposed reversely until day 8 for indicated period of 
time to 0.1 μM rotenone and 5 μM MPP+. On day 8, compounds were 
washed out and cells recovered for further 7 days. Chronic/repeat-dose 
(fresh substance was added with each medium exchange) exposure 
(192 h, from day 7 until day 15) was included as positive control. Cell 
viability was analyzed using resazurin reduction assay. Cell viability is 
presented in  % of solvent-treated controls in at least three independ-
ent experiments (n ≥ 3, mean ± SEM, n = 2 for MPP+ on day 15). d 
Mitochondrial membrane potential in individual LUHMES aggregates, 
exposed to rotenone for 48 h from day 6 to 8 measured by Mitotracker 
assay. Fluorescence intensity was measured as mean gray values using 
ImageJ software and normalized to the size and then to the fluores-
cence intensity of DMSO control aggregates (n = 3), at least 10 aggre-
gates were assayed for each independent experiment, ***p < 0.001, 
Kruskal–Wallis followed by Dunn’s post hoc test)
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0.5 μM), which was not as closely related for the higher 
cytotoxic concentrations (1 and 10 μM), where changes in 
morphology and size of the aggregates prohibited precise 
microscopic evaluation of MitoTracker samples.
There are some limitations in imaging 3D cultures. 
Since 3D aggregates are ≥200 μm thick, imaging them 
using conventional fluorescence microscopy is very chal-
lenging due to issues with light scattering and penetration 
depth. Advanced confocal microscopy and/or two-photon 
microscopy in combination with optical clearing by treat-
ment of the tissue with Scale clearing solution (Hama 
et al. 2011) prior to imaging overcome these limitations. 
Previously, it has been shown that rotenone perturbs neu-
rite integrity in 2D LUHMES cultures (Schildknecht et al. 
2013; Krug et al. 2013). To confirm these findings and to 
optimize the imaging of neurite integrity in 3D cultures, 
RFP-expressing LUHMES were used. Wild-type LUHMES 
were mixed with RFP-expressing LUHMES in the ratio 
49:1 on day 0 of differentiation and differentiated following 
the 3D + T10 protocol. It was shown previously that RFP 
is only expressed in viable cells (Schildknecht et al. 2013). 
After rotenone treatment from days 6 to 8 of differentiation, 
RFP-expressing viable cells within the aggregates were 
imaged using confocal microscopy for neurite quantifica-
tion. Exposure of LUHMES aggregates to 0.1 μM rotenone 
significantly affected the neurite integrity in comparison 
with DMSO controls (Fig. 7a, b). Thus, application of the 
fluorescent cell line mixed with wild-type cells helped to 
overcome the limitation of image quantification in these 
highly compact three-dimensional cultures.
Exposure of the 3D LUHMES model to rotenone 
and MPP+ alters the expression of genes involved 
in transsulfuration and one‑carbon metabolic pathways
The performance of the 3D model for toxicological studies 
was analyzed by gene expression. We have chosen a panel 
of candidate genes which were shown to be involved in cel-
lular adaptation to MPP+ exposure in 2D LUHMES cul-
tures by regulating central carbon metabolism and amino 
acid turnover (ASS1, argininosuccinate synthase, SHMT2, 
serine hydroxymethyl transferase), transsulfuration path-
way [CTH, cystathionase (cystathionine γ-lyase)], oxida-
tive stress and DNA replication and repair [TYMS, thymi-
dylate synthetase MLF1IP, centromere protein U (MLF 
interacting protein)] in earlier studies (Krug et al. 2014). 
LUHMES were differentiated following the 3D + T10 pro-
tocol and exposed to 0.1 μM rotenone and 5 μM MPP+ 
for 12 and 24 h on day 7 (Fig. 8a). In agreement with our 
earlier studies (Krug et al. 2014), on day 8—immediately 
after exposure—we observed the same regulation trends 
of those genes by rotenone and MPP+ [Fig. 8b, c, dark 
Fig. 7  Neurite integrity in individual LUHMES aggregates exposed 
to rotenone. a Exposure to 0.1 μM rotenone for 48 h from d6 to d8 
perturbed neurite integrity. Confocal images showing RFP-expressing 
cells (red) mixed in a 1:49 ratio with wild-type cells and differentiated 
following the 3D + T10 protocol for 8 days. Note rotenone-altered 
neurite integrity of viable RFP-expressing cells in comparison with 
DMSO control samples. Nuclei are stained with Hoechst 33342. Scale 
bars are 50 μm. b Quantification of neurite area in rotenone-treated 
samples versus DMSO controls, normalized to the number of RFP-
positive cell bodies in three independent experiments (nine aggregates 
were quantified for rotenone-treated samples and 12 for DMSO control 
samples) (n = 3, **p < 0.01, Mann–Whitney test) (color figure online)
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bars (rotenone), Supplementary Figure S3 (MPP+)]. Gene 
expression analysis was performed in three to four inde-
pendent experiments (up to 12 technical replicates) and 
normalized to DMSO-treated controls. ASS1 was the most 
strongly up-regulated gene by MPP+ (FC = 3.3, 24 h) and 
rotenone (FC = 2.4, 24 h). ATF4, activating transcription 
factor four, was identified as upstream regulator of the cel-
lular cascades initiated by MPP+ (Krug et al. 2014) but was 
less up-regulated in our 3D model by rotenone (FC = 1.5, 
24 h), though 2.3 times increased by 24-h MPP+ treatment. 
CTH and SHMT2 were more up-regulated by MPP+ than 
by rotenone. MLF1IP and TYMS were significantly down-
regulated in the 3D system following MPP+ and rotenone 
treatment. As proof-of-concept experiments—to study cel-
lular counter-regulation—rotenone was washed out on day 
8 of differentiation, and cells were kept in culture for fur-
ther 7 days. Since washout of 5 μM MPP+ did not prevent 
cell death, we analyzed the expression of the same panel of 
genes on day 15 only in rotenone-treated samples (Fig. 8b, 
c, light bars). Interestingly, ASS1, CTH, and SHTM2, which 
were up-regulated immediately after exposure, were down-
regulated 7 days later after rotenone withdrawal (Fig. 8b), 
while down-regulated genes (MLF1IP and TYMS) were 
further repressed with an even stronger effect (Fig. 8c). 
ATF4 was only slightly up-regulated on day 8 and returned 
to control level 7 days after recovery (Fig. 8b). This obser-
vation suggests that certain genes and signaling pathways 
are counter-regulated and/or may be responsible for cel-
lular recovery after the primary hit, while other processes 
cannot be restored and, thus, might be a part of the new 
cellular homeostasis.
Altered expression of mir‑7 miRNA after exposure 
of 3D LUHMES to rotenone
Finally, miRNAs involved in mitochondrial functions and 
relevant for PD were analyzed after exposure of LUHMES 
aggregates to 0.1 μM rotenone. In order to test whether 
miRNAs are involved in the recovery process, miRNA 
expression was assessed on day 8 as the reaction to the 
primary toxicant hit and on day 15, 7 days after rote-
none withdrawal (refer to Fig. 8a for treatment and sam-
pling scheme). In agreement with the literature showing 
down-regulation of mir-7 in PD models (Junn et al. 2009; 
Fragkouli and Doxakis 2014), we observed a reduction 
of miR-7 expression as early as 12 h after rotenone treat-
ment (Fig. 8b, dark bar), while known pro-apoptotic miR-
16 remained at control level (Fig. 8c). No changes were 
observed in expression of miR-210 (hypoxia-sensitive 
miRNA, involved in mitochondrial respiration (Chan et al. 
2012, data not shown), suggesting mir-7 as a primary 
rotenone miRNA target prior to mitochondria-mediated 
apoptosis. On day 15 after rotenone washout, however, 
mir-7 expression went back to control levels, grouping 
this miRNA together with other counter-regulated genes 
(Fig. 8b), suggesting a possible role of this miRNA in cel-
lular adaptation and recovery. In addition, brain-specific 
miRNA, mir-124, was unchanged on day 8 of differentia-
tion and was upregulated on day 15 after washout (data not 
shown).
Fig. 8  Time-dependent perturbations of gene expression after expo-
sure of 3D LUHMES to rotenone. a Toxicant treatment and washout 
scheme: LUHMES were differentiated following 3D + T10 proto-
col; exposure to 0.1 μM rotenone occurred for 12 or 24 h from day 
7 until day 8; Samples were collected for RT-PCR immediately after 
exposure on day 8 (dark arrow) or after rotenone washout and 7 days 
recovery on day 15 (light arrow). b Protein coding genes (ASS1, AT4, 
CTH, SHMT2) and miRNA (mir-7) with counter-regulation pattern 
after rotenone washout in comparison with acute response. c Protein 
coding genes (MLF1IP, TYMS) and miRNA (mir-16) with stronger 
response after rotenone withdrawal in comparison with acute tox-
icity. Dark bars show expression of the genes on day 8, while light 
bars show expression of the genes after rotenone washout and 7-day 
recovery. The data are means of log2 (fold change) ± SEM of at least 
three independent experiments (9–12 technical replicates). (n ≥ 3, 
*p < 0.05, **p < 0.01, and ***p < 0.001, one-way-ANOVA followed 
by Dunnett’s post hoc test)
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Discussion
The information gained from acute cytotoxicity studies 
appears to be of limited relevance for the understanding of 
chronic/slow-developing processes and low-dose chemi-
cal exposures (Hengstler et al. 2012). This situation also 
holds true for the study of neurodegenerative diseases such 
as Parkinson’s disease. Moreover, there are indications that 
the use of rodent models and cells may have low predic-
tivity for human disease states (Hartung 2008; Leist and 
Hartung 2013; Leist et al. 2014), and therefore, attempts 
are ongoing to provide toxicological/disease models on the 
basis of human cells (Krause et al. 2013).
At present, there are only few options to work with 
human dopaminergic neurons in long-term experiments. 
Therefore, the primary aim of this work was to adapt the 
LUHMES neuronal model (Scholz et al. 2011) to 3D. 
Besides emerging evidence in the literature pointing out 
the general advantages of 3D cell systems over classical 
monolayer cultures (Alépée et al. 2014), the main reason 
for attempting the 3D LUHMES model here was the oppor-
tunity for prolonged cultivation and increased cell survival 
after induction of differentiation. The 2D LUHMES model 
has been used successfully to study neurotoxicity, espe-
cially related to Parkinson’s (Schildknecht et al. 2009; Stie-
gler et al. 2011; Schildknecht et al. 2013; Krug et al. 2013, 
2014; Zhang et al. 2014; Ste˛pkowski et al. 2015). Several 
neurotoxicological end points were established for mon-
olayer LUHMES cultures, such as neurite outgrowth (Krug 
et al. 2013), Tau phosphorylation and associated cell death 
(Selenica et al. 2007), reporter cell line-based assays using 
high-content imaging (Schildknecht et al. 2013; van Vliet 
et al. 2014), omics technologies to study perturbations in 
cellular metabolism, and gene expression after toxicant 
exposure (Krug et al. 2014). However, in prolonged three-
dimensional cultures, cellular junctions are more in vivo-
like conditions and allow pronounced neuronal network 
formation. In addition, the specific composition of the 
extracellular matrix in the brain, which differs significantly 
from that of other organs (Yamaguchi 2000) and was shown 
to promote synaptogenesis and neuronal network formation 
(Dityatev and Fellin 2008; Frischknecht and Gundelfinger 
2012), and the lack of glia support, may make 2D neuronal 
cultures more sensitive and less adherent to cell culture 
plastic ware.
We adapted the LUHMES differentiation protocol to 3D 
applying a gyratory shaking technic (Honegger and Mon-
net-Tschudi 2001) and showed prolonged survival in 3D in 
comparison with 2D cultures (Fig. 1b, c). A frequent con-
cern about 3D cultures is the potential insufficient nutrient 
and oxygen supply to the center of aggregates (Minchinton 
and Tannock 2006; Derda et al. 2009). We demonstrated 
that the gyratory shaking method of LUHMES spheroid 
cultivation combined with taxol treatment allows con-
trolled spheroid size and fast penetration of compounds, 
for the example of Hoechst 33342 dye, into the middle of 
aggregates. Nuclei staining with Hoechst 33342, as well as 
caspase 3/7 staining, ensured the absence of cell death in 
the center of aggregates during differentiation (Fig. 2a–c). 
The absence of proliferating cells after 48-h taxol treat-
ment (Fig. 3) also proved the efficient penetration of the 
drug throughout the aggregates. Demonstration of penetra-
tion of relatively large molecules such as positive-charged 
Hoechst 33342 (Mw = 616 g/mol) and uncharged taxol 
(Mw = 854 g/mol) throughout the aggregates ensures that 
the model is suitable for compound testing.
LUHMES cells formed a pronounced neuronal net-
work and continued to mature further in 3D at later days 
of differentiation as shown in Fig. 4a, b (note increase in 
synaptophysin-stained cells, as well as advanced neuronal 
network from day 12 to day 21 of differentiation), showing 
the importance of keeping cultures longer for neuronal net-
work formation and synaptogenesis studies. Although the 
LUHMES 3D model consists of homotypic aggregates, we 
were surprised to observe cellular organization and polar-
ity within the aggregates similar to organotypical spheroids 
described by (Lancaster et al. 2013) as shown in Figs. 4a, 
5a for MAP2-positive cells, accumulating at one side of the 
aggregate starting on day 12 and onwards. This observa-
tion suggests that MAP2-positive cells may migrate from 
the initial differentiation area through the aggregate during 
maturation. A similar pattern was also observed for syn-
aptophysin staining but not for NF200, which was equally 
distributed throughout the aggregates at all stages of differ-
entiation (Fig. 4a, b). Further experiments using combina-
tions of live imaging techniques and RFP/GFP expression 
LUHMES may clarify this observation.
Especially for long-term exposures in vivo (where 
organ toxicities are recorded), the first organ to decompen-
sate leads the toxicity. Therefore, in vitro it is important 
to measure not only the reaction of cells to a hard, single 
hit, if we want to evaluate neurodegenerative processes or 
degenerative diseases. Instead, we should rather measure 
the potential to compensate/recover from multiple subtoxic 
hits, and over longer periods. Such differences are impor-
tant to work out to follow the new toxicological strategies 
suggested by the national research council (US) in 2007 
(NRC 2007). Thus, the long-term shelf life of our model 
may allow designing such experiments.
In this study, we used the well-known dopaminergic neu-
ronal toxicants MPP+ and rotenone as model compounds. 
MPP+ is a toxic metabolite of 1-methyl-4-phenyl-1.2.3.6-
tetrahydropyridine (MPTP), and rotenone is a broadly used 
pesticide. Both MPTP and rotenone are highly lipophilic, 
2740 Arch Toxicol (2016) 90:2725–2743
1 3
which makes it very easy for them to cross the blood–brain 
barrier, and they represent prime examples of mitochon-
drial toxins (Miller et al. 2009). Both compounds accumu-
late in mitochondria and inhibit complex I of the electron 
transport (respiratory) chain, a major target of ROS and the 
reason they are used in animal models to study Parkinson-
ism (Langston et al. 1984; Betarbet et al. 2000). As a proof 
of concept, LUHMES were differentiated in 3D, exposed 
either to MPP+ or rotenone for a short period of time (12, 
24, or 48 h); then, the compounds were washed out, and 
cells were cultivated for a further 7 days. First, we observed 
a similar cytotoxicity on day 8 in 3D as in our earlier stud-
ies in monolayer cultures (Fig. 6a, b; Krug et al. 2014), 
as measured by the resazurin reduction assay. Second, we 
confirmed perturbation of genes involved in one-carbon 
metabolism and transsulfuration pathways (ASS1, CTH, and 
SHTM2), on day 8 after 12 or 24 h of exposure to MPP+ and 
rotenone (Fig. 8b, c; Supplementary Figure S3; Krug et al. 
2014). Interestingly, MPP+ effects were stronger on certain 
genes than those of rotenone (much stronger induction of 
ASS1 and AT4, SHMT2, and CTH, for example). Third, we 
showed a down-regulation of PD-relevant mir-7 as early as 
12 h after rotenone exposure, while pro-apoptotic mir-16 
and rotenone-sensitive mir-210 were not yet significantly 
perturbed (Fig. 8b, c and data not shown). Finally, washout 
experiments demonstrated different counter-regulation after 
short-term exposures to sub-cytotoxic concentrations of 
rotenone or MPP+. The 3D cultures allow moving the aggre-
gates into a new cell culture dish, thus avoiding remaining 
toxicant contamination (e.g., compound bout to plastic), 
which represents an enormous advantage over 2D cultures 
for resilience studies. Interestingly, 5 μM MPP+ was not 
cytotoxic 24 h after exposure, but MPP+ withdrawal was 
not sufficient, and 80 % of cells were dead after the 7-day 
recovery period, likely due to the accumulation of MPP+ 
within the cells. 0.1 μM rotenone decreased cell viability by 
20 % after 24 h, which was further decreased by additional 
16 % after rotenone withdrawal (Fig. 6c). The molecular 
mechanisms, which prevented 64 % of cells from death in 
rotenone samples after washout, shall be addressed in future 
experiments. We observed different patterns of gene expres-
sion after 7 days of recovery. Genes down-regulated by 
rotenone, MLF1IP and TYMS, were further down-regulated, 
while mir-7 returned to normal level with a slight tendency 
for up-regulation. mir-7 is one of the few known miRNAs 
related to PD (reviewed in Mouradian 2012; Kaidery et al. 
2013). One of mir-7’s confirmed targets is α-synuclein, a 
major player in PD pathogenesis (Junn et al. 2009). Over-
expression of mir-7 in murine primary cortical neurons prior 
to exposure to MPP+ demonstrated a neuroprotective effect 
against MPP+ through activation of TOR pathway (Fragk-
ouli and Doxakis 2014). Recently, mir-7 was shown to pro-
tect SH-SY5Y cells against MPP+-induced cell death by 
targeting RelA (a component of nuclear factor-κB (NF-κB) 
(Choi et al. 2014). These studies, together with our findings, 
suggest a possible role of this miRNA in counter-regulation 
against the stress and for cellular resilience after exposure 
to the mitochondria toxicants MPP+ and rotenone. Here, for 
the first time, we demonstrated a significant down-regula-
tion of mir-7 expression by rotenone and its complete recov-
ery after rotenone withdrawal in a human-relevant Parkin-
son’s disease in vitro model. Further functional studies are 
needed to confirm this observation. In contrast, rotenone-
induced ASS1, SHTM2, and CTH were down-regulated after 
rotenone withdrawal (Fig. 8b), which could also be involved 
in counter-regulation mechanisms.
A further advantage of the longer-lived 3D LUHMES 
model over monolayer cultures could be the easier co-
culture and readout of LUHMES with other cell types, 
e.g., astrocytes or liver cells. 3D aggregates can be added 
to monolayer cultures of astrocytes or liver cells for the 
time of exposure without mixing the two cell populations 
as with 2D cultures (Efrémova et al. 2015). After exposure, 
the response to the toxicant treatment can be assessed sepa-
rately for LUHMES spheres and the other cell types. This 
may allow for the study of neuroprotective effects of fac-
tors released by glial cells and inclusion of metabolic com-
petence (liver cells) in the model.
In addition, the 3D LUHMES model may allow us to 
study the protective effects of Parkinson’s drug therapies by 
first exposing the cells to the toxicant and then to the drug. 
Thus, the model may have the potential for restorative/dis-
ease-modifying drug screening. Using reporter cell lines, in 
combination with quantitative high-content imaging, may 
contribute significantly to Parkinson’s drug screening (Schil-
dknecht et al. 2013). The introduction of the fluorescent 
cell lines into the wild-type LUHMES population in low 
percentage allows clear visualization of neurites and their 
assignment to the corresponding cell bodies. Quantification 
of cellular and neurite morphology in the mixed cultures of 
fluorescent cell lines, together with wild-type LUHMES as 
described in our proof-of-concept experiment in Fig. 7, can 
be used for the fast screening of potential toxicants (van 
Vliet et al. 2014) contributing to disease development as well 
as the efficiency of newly developed treatments.
In conclusion, we have established a 3D LUHMES 
model that will allow analysis of the long-term effects of 
toxicant exposure, such as delayed response to the toxicant 
insult, cellular resilience, and/or adaptation to a new home-
ostasis after toxicant withdrawal (discussed in Smirnova 
et al. 2015b).
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